Education
About Us
Working with TipRanks
Follow Us
Balaxi Pharmaceuticals Limited (IN:BALAXI)
:BALAXI
Total Valuation
Balaxi Pharmaceuticals Limited has a market cap or net worth of ₹476.44M. The enterprise value is ₹5.61B.
Market Cap₹476.44M
Enterprise Value₹5.61B
Share Statistics
Balaxi Pharmaceuticals Limited has 11,041,500 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding11,041,500
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Balaxi Pharmaceuticals Limited’s return on equity (ROE) is 0.11 and return on invested capital (ROIC) is 8.76%.
Return on Equity (ROE)0.11
Return on Assets (ROA)0.08
Return on Invested Capital (ROIC)8.76%
Return on Capital Employed (ROCE)0.11
Revenue Per Employee56.64M
Profits Per Employee4.92M
Employee Count51
Asset Turnover0.93
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Balaxi Pharmaceuticals Limited is 11.9. Balaxi Pharmaceuticals Limited’s PEG ratio is -0.01.
PE Ratio11.9
PS Ratio1.28
PB Ratio1.60
Price to Fair Value1.60
Price to FCF-6.29
Price to Operating Cash Flow0.00
PEG Ratio-0.01
Income Statement
In the last 12 months, Balaxi Pharmaceuticals Limited had revenue of 2.89B and earned 250.70M in profits. Earnings per share was 4.53.
Revenue2.89B
Gross Profit1.18B
Operating Income286.70M
Pretax Income286.70M
Net Income250.70M
EBITDA305.64M
Earnings Per Share (EPS)4.53
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
Balaxi Pharmaceuticals Limited pays an annual dividend of ₹0.5, resulting in a dividend yield of ―
Dividend Per Share₹0.5
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.98
52-Week Price Change-59.59%
50-Day Moving Average46.87
200-Day Moving Average58.39
Relative Strength Index (RSI)32.16
Average Volume (3m)113.96K
Important Dates
Balaxi Pharmaceuticals Limited upcoming earnings date is Oct 31, 2025, TBA (Confirmed).
Last Earnings DateAug 5, 2025
Next Earnings DateOct 31, 2025
Ex-Dividend DateJul 01, 2022
Financial Position
Balaxi Pharmaceuticals Limited as a current ratio of 4.45, with Debt / Equity ratio of 23.05%
Current Ratio4.45
Quick Ratio4.45
Debt to Market Cap0.14
Net Debt to EBITDA0.46
Interest Coverage Ratio9.77
Taxes
In the past 12 months, Balaxi Pharmaceuticals Limited has paid 35.99M in taxes.
Income Tax35.99M
Effective Tax Rate0.13
Enterprise Valuation
Balaxi Pharmaceuticals Limited EV to EBITDA ratio is 12.58, with an EV/FCF ratio of -6.53.
EV to Sales1.33
EV to EBITDA12.58
EV to Free Cash Flow-6.53
EV to Operating Cash Flow-10.17
Balance Sheet
Balaxi Pharmaceuticals Limited has ₹608.67M in cash and marketable securities with ₹0.00 in debt, giving a net cash position of ₹608.67M billion.
Cash & Marketable Securities₹608.67M
Total Debt₹0.00
Net Cash₹608.67M
Net Cash Per Share₹55.13
Tangible Book Value Per Share₹37.08
Margins
Gross margin is 43.32%, with operating margin of 9.93%, and net profit margin of 8.68%.
Gross Margin43.32%
Operating Margin9.93%
Pretax Margin9.93%
Net Profit Margin8.68%
EBITDA Margin10.58%
EBIT Margin9.93%
Analyst Forecast
The average price target for Balaxi Pharmaceuticals Limited is ₹48.00, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target₹48.00
Price Target Upside11.24% Upside
Analyst ConsensusHold
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast―